Antibody-mediated prevention and treatment of HIV-1 infection

Antibodies to watch in 2018

(2018) Hélène Kaplon et al.   mAbs

A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection

(2018) Rajeev Gautam et al.   NATURE MEDICINE

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

(2018) Martin R. Gaudinski et al.   PLOS MEDICINE

Relationship between latent and rebound viruses in a clinical trial of anti–HIV-1 antibody 3BNC117

(2018) Yehuda Z. Cohen et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

(2018) Pilar Mendoza et al.   NATURE

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

(2018) Yotam Bar-On et al.   NATURE MEDICINE

Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

(2018) Brinda Emu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys

(2018) Erica N. Borducchi et al.   NATURE

Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys

(2017) Boris Julg et al.   JOURNAL OF VIROLOGY

Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys

(2017) Boris Julg et al.   JOURNAL OF VIROLOGY

Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells

(2017) Yehuda Z. Cohen et al.   JOURNAL OF VIROLOGY

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

(2017) David A Margolis et al.   LANCET

Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults

(2017) Yunda Huang et al.   mAbs

Early antibody therapy can induce long-lasting immunity to SHIV

(2017) Yoshiaki Nishimura et al.   NATURE

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

(2017) Marina Caskey et al.   NATURE MEDICINE

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

(2017) Ling Xu et al.   SCIENCE

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge

(2017) Boris Julg et al.   Science Translational Medicine

Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller

(2017) Natalia T. Freund et al.   Science Translational Medicine

Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail

(2017) Boris Julg et al.   Science Translational Medicine

Prediction of HIV-1 sensitivity to broadly neutralizing antibodies shows a trend towards resistance over time

(2017) Anna Hake et al.   PLoS Computational Biology

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial

(2017) Kenneth H. Mayer et al.   PLOS MEDICINE

Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques

(2016) Brian Moldt et al.   AIDS

Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design

(2016) Dennis R. Burton et al.   Annual Review of Immunology

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency

(2016) Stylianos Bournazos et al.   CELL

Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity

(2016) Yaoxing Huang et al.   CELL

Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo

(2016) Maud Deruaz et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

(2016) Johannes F. Scheid et al.   NATURE

A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges

(2016) Rajeev Gautam et al.   NATURE

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques

(2016) Ann J Hessell et al.   NATURE MEDICINE

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

(2016) Katharine J. Bar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA

(2016) Julio C. C. Lorenzi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1

(2016) T. Schoofs et al.   SCIENCE

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo

(2016) C.-L. Lu et al.   SCIENCE

Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus

(2016) Jinyan Liu et al.   SCIENCE

Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1

(2015) Shuzo Matsushita et al.   AIDS

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

(2015) J. E. Ledgerwood et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

HIV-1 Fitness Cost Associated with Escape from the VRC01 Class of CD4 Binding Site Neutralizing Antibodies

(2015) Rebecca M. Lynch et al.   JOURNAL OF VIROLOGY

Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection

(2015) Kevin O. Saunders et al.   JOURNAL OF VIROLOGY

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

(2015) Marina Caskey et al.   NATURE

Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women

(2015) Jeanne M. Marrazzo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants

(2015) Julian K-C. Ma et al.   PLANT BIOTECHNOLOGY JOURNAL

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

(2015) Rebecca M. Lynch et al.   Science Translational Medicine

A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo

(2015) Natalia T. Freund et al.   PLoS Pathogens

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

(2015) Ole S. Søgaard et al.   PLoS Pathogens

Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity

(2014) Stylianos Bournazos et al.   CELL

Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice

(2014) Ariel Halper-Stromberg et al.   CELL

Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy

(2014) Anthony P. West et al.   CELL

Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants

(2014) Florian Klein et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

(2014) Masashi Shingai et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo

(2014) R. S. Rudicell et al.   JOURNAL OF VIROLOGY

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

(2014) Sung-Youl Ko et al.   NATURE

Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission

(2014) Alejandro B Balazs et al.   NATURE MEDICINE

MABGEL 1: First Phase 1 Trial of the Anti-HIV-1 Monoclonal Antibodies 2F5, 4E10 and 2G12 as a Vaginal Microbicide

(2014) Georgina C. Morris et al.   PLoS One

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor

(2014) A. Pegu et al.   Science Translational Medicine

Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies

(2013) Ron Diskin et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Neutralizing Polyclonal IgG Present during Acute Infection Prevents Rapid Disease Onset in Simian-Human Immunodeficiency Virus SHIVSF162P3-Infected Infant Rhesus Macaques

(2013) J. P. Jaworski et al.   JOURNAL OF VIROLOGY

Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques

(2013) C Moog et al.   Mucosal Immunology

Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia

(2013) Masashi Shingai et al.   NATURE

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys

(2013) Dan H. Barouch et al.   NATURE

Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1

(2013) C. S. Pace et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

(2013) J. A. Horwitz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration

(2012) Livio Azzoni et al.   JOURNAL OF INFECTIOUS DISEASES

Broadly Neutralizing Antibodies Developed by an HIV-Positive Elite Neutralizer Exact a Replication Fitness Cost on the Contemporaneous Virus

(2012) D. N. Sather et al.   JOURNAL OF VIROLOGY

A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced Fc RIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques

(2012) B. Moldt et al.   JOURNAL OF VIROLOGY

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice

(2012) Florian Klein et al.   NATURE

A mouse model for HIV-1 entry

(2012) J. Pietzsch et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo

(2012) B. Moldt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model

(2012) Milena Veselinovic et al.   VIROLOGY

Antibody-based protection against HIV infection by vectored immunoprophylaxis

(2011) Alejandro B. Balazs et al.   NATURE

Broad neutralization coverage of HIV by multiple highly potent antibodies

(2011) Laura M. Walker et al.   NATURE

Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges

(2011) Federico Mingozzi et al.   NATURE REVIEWS GENETICS

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

(2011) D. R. Burton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

(2011) J. F. Scheid et al.   SCIENCE

Correlates of Protection Induced by Vaccination

(2010) S. A. Plotkin   Clinical and Vaccine Immunology

Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques

(2010) Cherie T Ng et al.   NATURE MEDICINE

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

(2010) X. Wu et al.   SCIENCE

Polyfunctional CD4+ T-Cell Induction in Neutralizing Antibody-Triggered Control of Simian Immunodeficiency Virus Infection

(2009) T. Yamamoto et al.   JOURNAL OF VIROLOGY

Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-L

(2009) A. J. Hessell et al.   JOURNAL OF VIROLOGY

Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm

(2009) M. D. Simek et al.   JOURNAL OF VIROLOGY

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

(2009) Ann J Hessell et al.   NATURE MEDICINE

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

(2009) L. M. Walker et al.   SCIENCE

Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers

(2009) Ann J. Hessell et al.   PLoS Pathogens

A method for identification of HIV gp140 binding memory B cells in human blood

(2008) Johannes F. Scheid et al.   JOURNAL OF IMMUNOLOGICAL METHODS